Vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection receptor (RET) are the main targets of vandetanib on MTC treatment [17]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.